process for manufacture of a dexamethasone containing formulation for oral administration

• 1. 一种含地塞米松的混悬剂的制备方法 [P] . 中国专利： CN113521001A . 2021-10-22
• 2. 含硒键的ROS响应型地塞米松脂质体及其制备方法和应用 [P] . 中国专利： CN112402378A . 2021-02-26
• 3. Process for manufacturing a dexamethasone-containing formulation for oral administration [P] . 欧洲知识产权局专利： EP1594471B1 . 2009-03-25

  机译： 制备用于口服的含地塞米松的制剂的方法

• 4. process for manufacture of a dexamethasone containing formulation for oral administration [P] . 德国专利： DE602004020187D1 . 2009-05-07

  机译： 含地塞米松口服制剂的制备方法

• 5. Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor [P] . 美国专利： US2006034915A1 . 2006-02-16

  机译： 用于口服的含地塞米松的制剂及其所需的制备方法

• 1. Bioequivalence Study of Two Hydrochlorothiazide Formulations after Oral Administration in Healthy Chilean Volunteers [J] . Fierro, Humberto, Rojas, 药剂与药理学：英文版 . 2016,第012期
• 2. Smart Process Manufacturing Systems: Deep Integration of Arti cialIntelligence and Process Manufacturing [J] . Feng Qian 工程（英文） . 2019,第006期
• 3. Recent advances in particulate drug delivery systems: Oral, pulmonary, and ophthalmic administrations [J] . Hirofumi Takeuchi, Kohei Tahara, Risako Onodera 亚洲药物制剂科学(英文) . 2016,第001期
• 4. Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing [J] . Leane Michael, Pitt Kendal, Reynolds Gavin K., Pharmaceutical development and technology . 2018,第1a10期
• 5. A novel approach to establishing the design space for the oral formulation manufacturing process [J] . Norioka T., Hayashi Y., Onuki Y., Chemical and Pharmaceutical Bulletin . 2013,第1期
• 6. A Novel Approach to Establishing the Design Space for the Oral Formulation Manufacturing Process [J] . Chemical and Pharmaceutical Bulletin . 2013,第1期
• 7. Formulation and Manufacturing Process Design for Pressure Sensitive Colon-Targeting Capsule as a Novel Lipoid Oral Drug Delivery System [C] . M. Murakami, J-H Cui, M. Iwata, China-Japan Symposium on Pharmaceutical Preparations and Particulate Design; 20060515-17; Shenyang(CN) . 2006
• 8. Formulation studies of lactic acid-producing bacteria for oral administration. [D] . Liou, Yow-Hwa Grace. 1986
• 9. The Influence of Formulation and Manufacturing Process Parameters on the Characteristics of Lyophilized Orally Disintegrating Tablets [O] . Rhys J. Jones, Ali Rajabi-Siahboomi, Marina Levina, 2011
• 10. A Novel Approach to Establishing the Design Space for the Oral Formulation Manufacturing Process [O] . Tadashi Norioka, Yoshihiro Hayashi, Yoshinori Onuki, 2013
• 11. Acute and Repeated Dose Toxicity Studies on Nsc 94100 Following Daily Oral Administration to Dogs and Monkeys and Acute Toxicity Following Oral Administration to Mice and Monkeys [R] . Rakieten, N., Schein, P. S., Davis, R. D. 1967

• 1. Impact of Bar-Code Medication Administration and Electronic Medication Administration Record System in Clinical Practice for an Effective Medication Administration Process [J] . Mohanaa Naidu ,Yeo Lee Yean Alicia . 健康（英文） . 2019,第5期
• 2. Oral Administration Following Subcutaneous Administration of FCV Vaccines Enhances Vaccine Efficacy against Challenge of a Highly Virulent Vs Feline Calicivirus [J] . Sing Rong ,Kim Floyd-Hawkins ,Vicki King . 疫苗（英文） . 2014,第2期
• 3. 两种含地塞米松的预处理方案对紫杉醇过敏反应预防效果的Meta分析 [C] . 蔡和平 ,张铃铃 ,杨黎 . 2010年中国药学大会暨第十届中国药师周大会 . 2010
• 4. 体外循环系统管路肝素-地塞米松复合涂层制备方法及最佳条件的筛选 [A] . 李鑫 . 2012